Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7201 to 7215 of 7689 results

  1. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

    Technology appraisal guidance
    Published
    26 June 2000

  2. Imanitib for chronic myeloid leukaemia (TA50)

    This guidance has been updated and replaced by NICE technology appraisal guidance 70 [Partially updated by NICE technology appraisal guidance 241].

    Technology appraisal guidance
    Published
    16 October 2002

  3. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA175)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Technology appraisal guidance
    Published
    22 July 2009

  4. Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

    This guidance has been updated and replaced by NICE technology appraisal guidance 439.

    Technology appraisal guidance
    Published
    26 August 2009

  5. Laparoscopic surgery for hernia (TA18)

    This guidance has been replaced by NICE technology appraisal guidance 83.

    Technology appraisal guidance
    Published
    23 January 2001

  6. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (TA182)

    This guidance has been replaced by NICE technology appraisal guidance 317.

    Technology appraisal guidance
    Published
    28 October 2009

  7. Guidance on the Selection of Prostheses for Primary Total Hip Replacement (TA2)

    This guidance has been updated and replaced by NICE technology appraisal guidance 304.

    Technology appraisal guidance
    Published
    26 April 2000

  8. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.

    Technology appraisal guidance
    Published
    27 October 2010

  9. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    27 October 2010

  10. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Technology appraisal guidance
    Last updated
    1 December 2014

  11. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Technology appraisal guidance
    Published
    23 January 2001

  12. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Technology appraisal guidance
    Published
    28 July 2010

  13. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Technology appraisal guidance
    Published
    25 August 2010

  14. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

    Technology appraisal guidance
    Published
    25 August 2010

  15. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    24 February 2010